As next-generation protein therapeutics become increasingly complex, overcoming manufacturing bottlenecks to maximize commercial viability has become a top priority for drug developers.

This white paper explores Mycenax’s N-1 Perfusion Platform, a strategic approach designed to transition from traditional methods to Intensified Fed-Batch (IFB) manufacturing. By utilizing a specialized two-stage workflow, we demonstrate how to elevate Viable Cell Density (VCD) to ultra-high levels during the expansion stage and maximize production duration through refined feeding regimens.

Key Insights from this White Paper:

• Massive Productivity Gains: Learn how the IFB platform achieves over a >3.5-fold increase in output, reaching a relative titer of 367% compared to conventional fed-batch processes.
• Precision Process Control: Discover how we utilize Cell Specific Perfusion Rate (CSPR) and Cell Specific Feed Rate (CSFR) to overcome metabolic limitations and maintain log-phase growth.
• Uncompromised Product Quality: Review data proving that ultra-high productivity is achieved while maintaining comparable monomer purity and low impurity profiles (HMW/LMW).
• Scalability & Validation: See results from 2L bioreactor scale-up runs that confirm the stability and commercial readiness of the intensified process.

Download the full white paper to discover how Mycenax’s advanced CDMO capabilities and N-1 perfusion technology can accelerate your path to commercial success.